Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

PMGC Holdings Inc. - Common Stock (NQ: ELAB )

4.180 +0.260 (+6.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about PMGC Holdings Inc. - Common Stock

< Previous 1 2 Next >
Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1
From PMGC Holdings Inc.
Via GlobeNewswire
PMGC Holdings Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance
From PMGC Holdings Inc.
Via GlobeNewswire
PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group
From PMGC Holdings Inc.
Via GlobeNewswire
PMGC Holdings Highlights Strong Capital Position: No Debt, Fully Funded, and Warrants Priced Above Market
From PMGC Holdings Inc.
Via GlobeNewswire
Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Announces Successful Submission of Pre-IND Meeting Request to FDA for EL-22, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1
From PMGC Holdings Inc.
Via GlobeNewswire
Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1
From PMGC Holdings Inc.
Via GlobeNewswire
PMGC Capital LLC, a subsidiary of PMGC Holdings Inc., Begins to Build Portfolio with Strategic Acquisition of shares in U.S.-Focused Uranium Energy and Fire Prevention Technology Companies
From PMGC Holdings Inc.
Via GlobeNewswire
Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement For Preclinical Mouse Study of EL-32, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1
From PMGC Holdings Inc.
Via GlobeNewswire
PMGC Holdings Inc. Announces $1.9 Million in Gross Proceeds from Warrant Inducement with Institutional Investors
From PMGC Holdings Inc.
Via GlobeNewswire
Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium
Northstrive Biosciences Inc. was invited to present EL-22, a novel myostatin asset aimed at preserving muscle while on weight loss treatments, at the UCLA Obesity Symposium called Anti-Obesity... 
From PMGC Holdings Inc.
Via GlobeNewswire
PMGC Holdings Inc. Announces Closing of Elevai Skincare Divestiture
Strategic Divestment Reduces Cash Burn and Enhances Operational Efficiency 
From PMGC Holdings Inc.
Via GlobeNewswire
PMGC Holdings Inc. Announces Name Change of Wholly Owned Subsidiaries
From PMGC Holdings Inc.
Via GlobeNewswire
PMGC Holdings Inc. Following Skincare Subsidiary Sale, Embarks on Bold Growth Strategy
From PMGC Holdings Inc.
Via GlobeNewswire
Carmell Announces Execution of Definitive Agreement to Acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair Care Products
From PMGC Holdings Inc.
Via GlobeNewswire
Elevai Labs Inc. Announces Name Change to PMGC Holdings Inc. and Redomicile to Nevada
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess
From Elevai Labs Inc.
Via GlobeNewswire
CORRECTION - Elevai Labs Inc.
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
From Elevai Labs Inc.
Via GlobeNewswire
MicroCaps Making Major Moves: DJT, BNOX, ELAB, PETV, RJDG in High-Growth Markets
Via AB Newswire
Topics Government
Exposures Political
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock
From Elevai Labs Inc.
Via GlobeNewswire
REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
From Elevai Labs Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.